Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 22 | 2020 | 207 | 3.820 |
Why?
|
Borrelia | 11 | 2011 | 25 | 2.700 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 6 | 2019 | 14 | 2.470 |
Why?
|
Relapsing Fever | 8 | 2008 | 16 | 1.960 |
Why?
|
Optic Neuritis | 5 | 2019 | 9 | 1.900 |
Why?
|
Brain | 12 | 2013 | 1488 | 1.670 |
Why?
|
Antibodies, Monoclonal | 5 | 2019 | 836 | 1.530 |
Why?
|
Muscular Dystrophy, Facioscapulohumeral | 5 | 2024 | 39 | 1.520 |
Why?
|
Interleukin-10 | 6 | 2011 | 149 | 1.520 |
Why?
|
Disability Evaluation | 10 | 2019 | 199 | 1.510 |
Why?
|
Borrelia Infections | 5 | 2010 | 11 | 1.500 |
Why?
|
Borrelia burgdorferi | 8 | 2016 | 68 | 1.340 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 5 | 2019 | 33 | 1.280 |
Why?
|
Lyme Disease | 7 | 2016 | 104 | 1.260 |
Why?
|
Lyme Neuroborreliosis | 5 | 2016 | 9 | 1.260 |
Why?
|
Immunologic Factors | 7 | 2018 | 103 | 1.170 |
Why?
|
Visual Acuity | 3 | 2019 | 117 | 1.130 |
Why?
|
Fragile X Syndrome | 2 | 2022 | 27 | 0.980 |
Why?
|
Disease Progression | 8 | 2022 | 1119 | 0.970 |
Why?
|
Bacterial Outer Membrane Proteins | 3 | 2010 | 121 | 0.960 |
Why?
|
Magnetic Resonance Imaging | 15 | 2022 | 2052 | 0.940 |
Why?
|
Nerve Tissue Proteins | 3 | 2019 | 418 | 0.930 |
Why?
|
Walking | 6 | 2016 | 228 | 0.910 |
Why?
|
Chemokine CXCL13 | 6 | 2011 | 8 | 0.910 |
Why?
|
Spirochaetales | 3 | 2010 | 4 | 0.760 |
Why?
|
Lipoproteins | 3 | 2011 | 80 | 0.760 |
Why?
|
Membrane Proteins | 3 | 2019 | 850 | 0.750 |
Why?
|
Endothelium, Vascular | 3 | 2011 | 169 | 0.720 |
Why?
|
Bacteremia | 3 | 2011 | 91 | 0.690 |
Why?
|
Female | 43 | 2024 | 30720 | 0.640 |
Why?
|
Male | 41 | 2024 | 27743 | 0.640 |
Why?
|
Visually Impaired Persons | 1 | 2019 | 13 | 0.640 |
Why?
|
Severity of Illness Index | 6 | 2018 | 1479 | 0.630 |
Why?
|
Antigens, Bacterial | 2 | 2010 | 200 | 0.620 |
Why?
|
Muscle, Skeletal | 5 | 2022 | 674 | 0.600 |
Why?
|
Central Nervous System Bacterial Infections | 2 | 2010 | 3 | 0.600 |
Why?
|
Chemokines, CXC | 4 | 2007 | 29 | 0.600 |
Why?
|
Humans | 54 | 2024 | 59374 | 0.590 |
Why?
|
Macaca mulatta | 6 | 2005 | 228 | 0.590 |
Why?
|
Adult | 28 | 2024 | 15679 | 0.580 |
Why?
|
Recovery of Function | 1 | 2019 | 270 | 0.570 |
Why?
|
Middle Aged | 27 | 2024 | 16312 | 0.570 |
Why?
|
Antibodies, Monoclonal, Humanized | 3 | 2013 | 217 | 0.540 |
Why?
|
Treatment Outcome | 9 | 2024 | 5281 | 0.540 |
Why?
|
Gadolinium DTPA | 3 | 2020 | 84 | 0.520 |
Why?
|
Apoptosis | 4 | 2011 | 1033 | 0.520 |
Why?
|
B-Lymphocytes | 4 | 2009 | 552 | 0.500 |
Why?
|
Inflammation | 4 | 2017 | 1098 | 0.500 |
Why?
|
Benchmarking | 1 | 2016 | 135 | 0.500 |
Why?
|
Blood-Brain Barrier | 6 | 2017 | 81 | 0.480 |
Why?
|
Exercise Test | 2 | 2013 | 242 | 0.480 |
Why?
|
Double-Blind Method | 5 | 2024 | 715 | 0.480 |
Why?
|
Glatiramer Acetate | 5 | 2016 | 6 | 0.470 |
Why?
|
Mice | 16 | 2019 | 10294 | 0.440 |
Why?
|
Animals | 23 | 2019 | 19650 | 0.430 |
Why?
|
Oligodendroglia | 1 | 2013 | 33 | 0.430 |
Why?
|
Interferon-beta | 5 | 2013 | 76 | 0.420 |
Why?
|
Young Adult | 10 | 2019 | 4272 | 0.420 |
Why?
|
Patient Outcome Assessment | 1 | 2013 | 52 | 0.410 |
Why?
|
Central Nervous System Diseases | 1 | 2013 | 56 | 0.410 |
Why?
|
Self Report | 1 | 2015 | 359 | 0.410 |
Why?
|
Simvastatin | 1 | 2012 | 26 | 0.400 |
Why?
|
Contrast Media | 4 | 2020 | 400 | 0.390 |
Why?
|
Interferon beta-1b | 4 | 2016 | 5 | 0.390 |
Why?
|
Mice, SCID | 6 | 2009 | 513 | 0.380 |
Why?
|
Encephalitis | 1 | 2012 | 34 | 0.380 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 735 | 0.370 |
Why?
|
Microcirculation | 2 | 2008 | 52 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 204 | 0.340 |
Why?
|
Antibodies, Bacterial | 6 | 2008 | 187 | 0.340 |
Why?
|
Longitudinal Studies | 7 | 2017 | 1189 | 0.340 |
Why?
|
Spirochaetales Infections | 1 | 2010 | 1 | 0.340 |
Why?
|
Time Factors | 9 | 2018 | 3615 | 0.340 |
Why?
|
Adolescent | 9 | 2019 | 5835 | 0.320 |
Why?
|
Acute Disease | 4 | 2019 | 658 | 0.320 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2020 | 651 | 0.320 |
Why?
|
Natalizumab | 4 | 2018 | 11 | 0.310 |
Why?
|
Neuropsychological Tests | 5 | 2014 | 371 | 0.300 |
Why?
|
Neurons | 2 | 2013 | 863 | 0.290 |
Why?
|
Evoked Potentials, Visual | 2 | 2018 | 13 | 0.290 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2008 | 527 | 0.290 |
Why?
|
Reproducibility of Results | 7 | 2022 | 1559 | 0.280 |
Why?
|
Cognition Disorders | 3 | 2014 | 215 | 0.280 |
Why?
|
Vestibular Diseases | 1 | 2007 | 9 | 0.280 |
Why?
|
Myocarditis | 2 | 2005 | 60 | 0.280 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 2379 | 0.270 |
Why?
|
Gadolinium | 4 | 2017 | 103 | 0.270 |
Why?
|
Surveys and Questionnaires | 4 | 2019 | 2516 | 0.260 |
Why?
|
Peptides | 4 | 2012 | 549 | 0.250 |
Why?
|
Root Canal Therapy | 2 | 2017 | 3 | 0.250 |
Why?
|
Radiography, Dental, Digital | 2 | 2017 | 3 | 0.250 |
Why?
|
Disease Models, Animal | 4 | 2004 | 2053 | 0.240 |
Why?
|
Cerebrovascular Circulation | 1 | 2006 | 174 | 0.240 |
Why?
|
T-Lymphocytes | 2 | 2007 | 986 | 0.240 |
Why?
|
Cyclopropanes | 2 | 2024 | 50 | 0.240 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2017 | 70 | 0.240 |
Why?
|
Borrelia burgdorferi Group | 1 | 2004 | 27 | 0.230 |
Why?
|
Pyridines | 2 | 2024 | 98 | 0.230 |
Why?
|
Mice, Knockout | 4 | 2011 | 1997 | 0.210 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2013 | 18 | 0.210 |
Why?
|
Heart Diseases | 1 | 2005 | 206 | 0.210 |
Why?
|
Cytokines | 2 | 2008 | 915 | 0.210 |
Why?
|
Homeodomain Proteins | 2 | 2020 | 254 | 0.210 |
Why?
|
Adipose Tissue | 2 | 2022 | 283 | 0.210 |
Why?
|
Spinal Cord | 1 | 2004 | 195 | 0.200 |
Why?
|
Hair Follicle | 1 | 2022 | 29 | 0.200 |
Why?
|
Serotyping | 3 | 2007 | 50 | 0.200 |
Why?
|
Polymerase Chain Reaction | 3 | 2009 | 495 | 0.200 |
Why?
|
Fragile X Mental Retardation Protein | 1 | 2022 | 38 | 0.200 |
Why?
|
Social Communication Disorder | 1 | 2022 | 2 | 0.190 |
Why?
|
Quality of Life | 4 | 2019 | 1137 | 0.190 |
Why?
|
Placebos | 2 | 2012 | 68 | 0.190 |
Why?
|
Cerebral Cortex | 2 | 2017 | 248 | 0.190 |
Why?
|
Inflammation Mediators | 1 | 2002 | 171 | 0.180 |
Why?
|
RNA, Messenger | 2 | 2022 | 1466 | 0.180 |
Why?
|
Cerebellar Nuclei | 1 | 2020 | 4 | 0.180 |
Why?
|
Phenotype | 1 | 2004 | 1137 | 0.180 |
Why?
|
Gray Matter | 1 | 2020 | 31 | 0.170 |
Why?
|
Cluster Analysis | 2 | 2012 | 245 | 0.170 |
Why?
|
Tooth Root | 2 | 2017 | 2 | 0.170 |
Why?
|
Immunocompromised Host | 3 | 2006 | 100 | 0.170 |
Why?
|
Chemokines | 2 | 2013 | 93 | 0.170 |
Why?
|
Bites and Stings | 3 | 2004 | 11 | 0.170 |
Why?
|
Electroencephalography | 2 | 2019 | 134 | 0.170 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 127 | 0.170 |
Why?
|
White Matter | 2 | 2019 | 114 | 0.160 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2019 | 8 | 0.160 |
Why?
|
Evoked Potentials, Auditory | 1 | 2019 | 10 | 0.160 |
Why?
|
DNA Primers | 2 | 2010 | 289 | 0.160 |
Why?
|
Myocardium | 3 | 2006 | 264 | 0.160 |
Why?
|
Retrospective Studies | 6 | 2020 | 6070 | 0.160 |
Why?
|
Ixodes | 3 | 2004 | 31 | 0.160 |
Why?
|
Pilot Projects | 1 | 2022 | 914 | 0.160 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 206 | 0.160 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 47 | 0.160 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 57 | 0.160 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 163 | 0.160 |
Why?
|
Optic Nerve | 1 | 2018 | 25 | 0.160 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 440 | 0.160 |
Why?
|
Retinal Ganglion Cells | 1 | 2018 | 27 | 0.150 |
Why?
|
Biomarkers | 2 | 2022 | 1306 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2019 | 151 | 0.150 |
Why?
|
Immunosuppressive Agents | 2 | 2012 | 365 | 0.150 |
Why?
|
Autism Spectrum Disorder | 1 | 2022 | 175 | 0.150 |
Why?
|
Mice, Inbred C57BL | 4 | 2019 | 3231 | 0.150 |
Why?
|
Antibodies | 2 | 2009 | 179 | 0.150 |
Why?
|
Hand | 1 | 2018 | 67 | 0.140 |
Why?
|
PubMed | 1 | 2017 | 10 | 0.140 |
Why?
|
Penicillin G | 1 | 2016 | 5 | 0.140 |
Why?
|
Cefotaxime | 1 | 2016 | 4 | 0.140 |
Why?
|
Amoxicillin | 1 | 2016 | 7 | 0.140 |
Why?
|
Ceftriaxone | 1 | 2016 | 19 | 0.140 |
Why?
|
Doxycycline | 1 | 2016 | 42 | 0.130 |
Why?
|
International Cooperation | 1 | 2017 | 84 | 0.130 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 446 | 0.130 |
Why?
|
Tomography, Optical Coherence | 1 | 2018 | 209 | 0.130 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 1027 | 0.130 |
Why?
|
Mice, Inbred BALB C | 2 | 2009 | 868 | 0.130 |
Why?
|
Upper Extremity | 1 | 2016 | 49 | 0.130 |
Why?
|
Myocytes, Cardiac | 2 | 2006 | 88 | 0.130 |
Why?
|
Hypophosphatemia | 1 | 2015 | 6 | 0.120 |
Why?
|
Psychometrics | 2 | 2014 | 362 | 0.120 |
Why?
|
Activities of Daily Living | 2 | 2014 | 289 | 0.120 |
Why?
|
DNA, Bacterial | 2 | 2006 | 259 | 0.120 |
Why?
|
Demography | 1 | 2015 | 169 | 0.120 |
Why?
|
Endothelial Growth Factors | 1 | 2014 | 20 | 0.120 |
Why?
|
Brain Injuries | 1 | 2016 | 135 | 0.120 |
Why?
|
Synovial Membrane | 1 | 2014 | 19 | 0.110 |
Why?
|
Aged | 6 | 2022 | 13406 | 0.110 |
Why?
|
RNA, Bacterial | 2 | 2004 | 68 | 0.110 |
Why?
|
Immunohistochemistry | 3 | 2005 | 847 | 0.110 |
Why?
|
Disabled Persons | 1 | 2016 | 189 | 0.110 |
Why?
|
Gait Disorders, Neurologic | 1 | 2013 | 17 | 0.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2007 | 294 | 0.110 |
Why?
|
Heart | 2 | 2007 | 274 | 0.110 |
Why?
|
Autoantibodies | 1 | 2014 | 172 | 0.110 |
Why?
|
Radiography, Bitewing | 1 | 2013 | 1 | 0.110 |
Why?
|
Dental Pulp Cavity | 1 | 2013 | 2 | 0.110 |
Why?
|
Interferon beta-1a | 1 | 2013 | 9 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 677 | 0.100 |
Why?
|
Dexamethasone | 2 | 2004 | 201 | 0.100 |
Why?
|
Employment | 1 | 2013 | 124 | 0.100 |
Why?
|
Neuroimaging | 1 | 2013 | 143 | 0.100 |
Why?
|
Follow-Up Studies | 3 | 2013 | 2338 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 2 | 2004 | 164 | 0.100 |
Why?
|
Cell Survival | 1 | 2013 | 559 | 0.090 |
Why?
|
Cell Line | 3 | 2020 | 1983 | 0.090 |
Why?
|
Remission Induction | 1 | 2011 | 137 | 0.090 |
Why?
|
fas Receptor | 1 | 2011 | 55 | 0.090 |
Why?
|
Caspase 3 | 1 | 2011 | 103 | 0.090 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 284 | 0.090 |
Why?
|
Mice, Inbred Strains | 1 | 2010 | 179 | 0.080 |
Why?
|
Drug Tolerance | 1 | 2009 | 29 | 0.080 |
Why?
|
Neurologic Examination | 1 | 2009 | 52 | 0.080 |
Why?
|
Molecular Conformation | 1 | 2009 | 133 | 0.080 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2010 | 145 | 0.080 |
Why?
|
Observer Variation | 1 | 2009 | 205 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2009 | 287 | 0.080 |
Why?
|
Prospective Studies | 2 | 2013 | 3067 | 0.080 |
Why?
|
In Situ Nick-End Labeling | 1 | 2008 | 43 | 0.080 |
Why?
|
Structure-Activity Relationship | 1 | 2009 | 365 | 0.080 |
Why?
|
Phylogeny | 1 | 2009 | 337 | 0.080 |
Why?
|
Coloring Agents | 1 | 2008 | 53 | 0.070 |
Why?
|
Cognition | 1 | 2012 | 454 | 0.070 |
Why?
|
Base Sequence | 1 | 2010 | 1302 | 0.070 |
Why?
|
Interferon Type I | 1 | 2009 | 169 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 1091 | 0.070 |
Why?
|
Aging | 1 | 2013 | 710 | 0.070 |
Why?
|
Recombinant Proteins | 1 | 2009 | 689 | 0.070 |
Why?
|
Killer Cells, Natural | 1 | 2008 | 218 | 0.070 |
Why?
|
Spleen | 1 | 2008 | 479 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2008 | 309 | 0.070 |
Why?
|
Arthritis | 1 | 2007 | 49 | 0.070 |
Why?
|
Hemorrhage | 1 | 2008 | 260 | 0.070 |
Why?
|
Primates | 1 | 2006 | 42 | 0.070 |
Why?
|
Immunoglobulins | 1 | 2006 | 76 | 0.070 |
Why?
|
Antibody Formation | 1 | 2006 | 108 | 0.070 |
Why?
|
Complement Activation | 1 | 2006 | 49 | 0.070 |
Why?
|
Interferon-gamma | 1 | 2008 | 551 | 0.060 |
Why?
|
Cells, Cultured | 1 | 2010 | 2092 | 0.060 |
Why?
|
Survival Rate | 1 | 2008 | 801 | 0.060 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2007 | 151 | 0.060 |
Why?
|
Down-Regulation | 1 | 2007 | 306 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 588 | 0.060 |
Why?
|
Caspases | 1 | 2006 | 166 | 0.060 |
Why?
|
Germinal Center | 1 | 2005 | 38 | 0.060 |
Why?
|
Nervous System | 1 | 2005 | 69 | 0.060 |
Why?
|
Brain Infarction | 1 | 2004 | 19 | 0.060 |
Why?
|
Safety | 1 | 2005 | 142 | 0.060 |
Why?
|
Mice, Inbred C3H | 1 | 2004 | 173 | 0.060 |
Why?
|
Complement C1q | 1 | 2004 | 8 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 238 | 0.060 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2004 | 34 | 0.060 |
Why?
|
Immunoenzyme Techniques | 1 | 2004 | 107 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2005 | 224 | 0.060 |
Why?
|
Aorta | 1 | 2004 | 108 | 0.060 |
Why?
|
Needles | 1 | 2003 | 65 | 0.050 |
Why?
|
Signal Transduction | 1 | 2013 | 2903 | 0.050 |
Why?
|
HIV Infections | 1 | 2010 | 913 | 0.050 |
Why?
|
Genotype | 1 | 2004 | 617 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2008 | 1151 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 130 | 0.050 |
Why?
|
Research Design | 2 | 2018 | 555 | 0.050 |
Why?
|
Child | 3 | 2022 | 4186 | 0.050 |
Why?
|
Area Under Curve | 1 | 2021 | 141 | 0.040 |
Why?
|
Macrophages | 1 | 2006 | 1015 | 0.040 |
Why?
|
Immunity, Innate | 1 | 2007 | 774 | 0.040 |
Why?
|
Muscle Cells | 1 | 2020 | 26 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 526 | 0.040 |
Why?
|
Administration, Oral | 1 | 2021 | 355 | 0.040 |
Why?
|
Cohort Studies | 2 | 2017 | 2375 | 0.040 |
Why?
|
Linear Models | 1 | 2020 | 403 | 0.040 |
Why?
|
Myelin Sheath | 1 | 2019 | 34 | 0.040 |
Why?
|
Chronic Disease | 1 | 2002 | 717 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2002 | 718 | 0.040 |
Why?
|
Cell Death | 1 | 2020 | 271 | 0.040 |
Why?
|
Nerve Fibers | 1 | 2018 | 29 | 0.040 |
Why?
|
Visual Perception | 1 | 2018 | 41 | 0.040 |
Why?
|
Visual Fields | 1 | 2018 | 43 | 0.040 |
Why?
|
Photic Stimulation | 1 | 2018 | 89 | 0.040 |
Why?
|
Software | 1 | 2020 | 366 | 0.030 |
Why?
|
Communication | 1 | 2022 | 545 | 0.030 |
Why?
|
Child, Preschool | 1 | 2022 | 1792 | 0.030 |
Why?
|
Image Enhancement | 1 | 2017 | 188 | 0.030 |
Why?
|
World Health Organization | 1 | 2014 | 30 | 0.030 |
Why?
|
Phosphates | 1 | 2015 | 90 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 275 | 0.030 |
Why?
|
Prognosis | 1 | 2018 | 1597 | 0.030 |
Why?
|
Space Perception | 1 | 2014 | 19 | 0.030 |
Why?
|
Acoustic Stimulation | 1 | 2014 | 50 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 185 | 0.030 |
Why?
|
Demyelinating Diseases | 1 | 2013 | 16 | 0.030 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 15 | 0.030 |
Why?
|
Calcium Sulfate | 1 | 2013 | 1 | 0.030 |
Why?
|
Dental Restoration, Temporary | 1 | 2013 | 1 | 0.030 |
Why?
|
Periapical Diseases | 1 | 2013 | 1 | 0.030 |
Why?
|
Root Canal Irrigants | 1 | 2013 | 1 | 0.030 |
Why?
|
Root Canal Obturation | 1 | 2013 | 1 | 0.030 |
Why?
|
Zinc Oxide-Eugenol Cement | 1 | 2013 | 1 | 0.030 |
Why?
|
Rubber Dams | 1 | 2013 | 1 | 0.030 |
Why?
|
Root Canal Preparation | 1 | 2013 | 1 | 0.030 |
Why?
|
Zinc Sulfate | 1 | 2013 | 1 | 0.030 |
Why?
|
Root Canal Filling Materials | 1 | 2013 | 2 | 0.030 |
Why?
|
Dental Restoration, Permanent | 1 | 2013 | 2 | 0.030 |
Why?
|
Methylmethacrylates | 1 | 2013 | 2 | 0.030 |
Why?
|
Anatomic Variation | 1 | 2013 | 6 | 0.030 |
Why?
|
Sodium Hypochlorite | 1 | 2013 | 12 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 1552 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2013 | 91 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2013 | 47 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 805 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2013 | 146 | 0.030 |
Why?
|
Memory | 1 | 2014 | 111 | 0.030 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2012 | 20 | 0.030 |
Why?
|
Microscopy | 1 | 2013 | 90 | 0.020 |
Why?
|
New York | 1 | 2012 | 134 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 931 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 589 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2009 | 136 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2009 | 149 | 0.020 |
Why?
|
Necrosis | 1 | 2004 | 140 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2005 | 645 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2005 | 446 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2004 | 5119 | 0.010 |
Why?
|
Risk Factors | 1 | 2004 | 4986 | 0.010 |
Why?
|